European regulators on Friday said that the Duchenne muscular dystrophy gene therapy Elevidys should not be approved ...

An investigation can reveal the secret history of one of Australia’s top scientists, whose faked data underpins a drug now ...

Researchers at Uppsala University have identified a promising therapeutic approach for the challenging blood cancer multiple ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood plasma cells, the British drugmaker said on Thursday.

FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.

Rocket Pharmaceuticals announced a restructuring that will include layoffs affecting 30% of its employees. The company is ...

The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment, the company said on Wednesday.

GSK said the U.S. Food and Drug Administration extended its review period for Blenrep combinations to treat patients with relapsed or refractory multiple myeloma.